SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet
SynAct Pharma AB (“SynAct”) today announce that the company´s pharmacokinetic study on new tablet formulations of AP1189 has been successfully completed. The data confirms the tablet formulation as superior to, the until now used, AP1189 suspension. Further clinical development of AP1189 will be conducted using the new tablet.The study was setup with three parts. In part 1 of the study, AP1189 formulated as fast release tablets, was tested in 12 healthy volunteers in cross over design with the previously used AP1189 suspension as control. The pharmacokinetic profile of the tablets was